JP7583710B2 - スパイン形成のためのファシン結合化合物 - Google Patents

スパイン形成のためのファシン結合化合物 Download PDF

Info

Publication number
JP7583710B2
JP7583710B2 JP2021510960A JP2021510960A JP7583710B2 JP 7583710 B2 JP7583710 B2 JP 7583710B2 JP 2021510960 A JP2021510960 A JP 2021510960A JP 2021510960 A JP2021510960 A JP 2021510960A JP 7583710 B2 JP7583710 B2 JP 7583710B2
Authority
JP
Japan
Prior art keywords
compound
formula
disease
pharma
fascin
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Active
Application number
JP2021510960A
Other languages
English (en)
Japanese (ja)
Other versions
JP2021535159A5 (enExample
JP2021535159A (ja
Inventor
ステラ ティー． サラフ，
ヴィンセント エフ． サイモン，
ピーター ダブリュー． ヴァンダークリシュ，
Original Assignee
スピノジェニックス， インコーポレイテッド
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by スピノジェニックス， インコーポレイテッド filed Critical スピノジェニックス， インコーポレイテッド
Publication of JP2021535159A publication Critical patent/JP2021535159A/ja
Publication of JP2021535159A5 publication Critical patent/JP2021535159A5/ja
Priority to JP2024192796A priority Critical patent/JP2025016676A/ja
Application granted granted Critical
Publication of JP7583710B2 publication Critical patent/JP7583710B2/ja
Active legal-status Critical Current
Anticipated expiration legal-status Critical

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
    • A61K31/425—Thiazoles
    • A61K31/426—1,3-Thiazoles
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/335—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
    • A61K31/415—1,2-Diazoles
    • A61K31/416—1,2-Diazoles condensed with carbocyclic ring systems, e.g. indazole
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/4353—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom ortho- or peri-condensed with heterocyclic ring systems
    • A61K31/4375—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom ortho- or peri-condensed with heterocyclic ring systems the heterocyclic ring system containing a six-membered ring having nitrogen as a ring heteroatom, e.g. quinolizines, naphthyridines, berberine, vincamine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
    • A61K31/4427—Non condensed pyridines; Hydrogenated derivatives thereof containing further heterocyclic ring systems
    • A61K31/4439—Non condensed pyridines; Hydrogenated derivatives thereof containing further heterocyclic ring systems containing a five-membered ring with nitrogen as a ring hetero atom, e.g. omeprazole
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/47—Quinolines; Isoquinolines
    • A61K31/472—Non-condensed isoquinolines, e.g. papaverine
    • A61K31/4725—Non-condensed isoquinolines, e.g. papaverine containing further heterocyclic rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/4965—Non-condensed pyrazines
    • A61K31/497—Non-condensed pyrazines containing further heterocyclic rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/50—Pyridazines; Hydrogenated pyridazines
    • A61K31/501—Pyridazines; Hydrogenated pyridazines not condensed and containing further heterocyclic rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
    • A61K31/513—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim having oxo groups directly attached to the heterocyclic ring, e.g. cytosine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
    • A61K31/519—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim ortho- or peri-condensed with heterocyclic rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/14—Drugs for disorders of the nervous system for treating abnormal movements, e.g. chorea, dyskinesia
    • A61P25/16—Anti-Parkinson drugs
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/24—Antidepressants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Epidemiology (AREA)
  • Biomedical Technology (AREA)
  • Neurosurgery (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Neurology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Organic Chemistry (AREA)
  • Psychiatry (AREA)
  • Hospice & Palliative Care (AREA)
  • Psychology (AREA)
  • Pain & Pain Management (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
JP2021510960A 2018-08-27 2019-08-27 スパイン形成のためのファシン結合化合物 Active JP7583710B2 (ja)

Priority Applications (1)

Application Number Priority Date Filing Date Title
JP2024192796A JP2025016676A (ja) 2018-08-27 2024-11-01 スパイン形成のためのファシン結合化合物

Applications Claiming Priority (7)

Application Number Priority Date Filing Date Title
US201862723381P 2018-08-27 2018-08-27
US62/723,381 2018-08-27
US201862726904P 2018-09-04 2018-09-04
US62/726,904 2018-09-04
US201862785435P 2018-12-27 2018-12-27
US62/785,435 2018-12-27
PCT/US2019/048408 WO2020046991A1 (en) 2018-08-27 2019-08-27 Fascin binding compounds for spinogenesis

Related Child Applications (1)

Application Number Title Priority Date Filing Date
JP2024192796A Division JP2025016676A (ja) 2018-08-27 2024-11-01 スパイン形成のためのファシン結合化合物

Publications (3)

Publication Number Publication Date
JP2021535159A JP2021535159A (ja) 2021-12-16
JP2021535159A5 JP2021535159A5 (enExample) 2022-08-25
JP7583710B2 true JP7583710B2 (ja) 2024-11-14

Family

ID=69644570

Family Applications (2)

Application Number Title Priority Date Filing Date
JP2021510960A Active JP7583710B2 (ja) 2018-08-27 2019-08-27 スパイン形成のためのファシン結合化合物
JP2024192796A Pending JP2025016676A (ja) 2018-08-27 2024-11-01 スパイン形成のためのファシン結合化合物

Family Applications After (1)

Application Number Title Priority Date Filing Date
JP2024192796A Pending JP2025016676A (ja) 2018-08-27 2024-11-01 スパイン形成のためのファシン結合化合物

Country Status (7)

Country Link
US (2) US20210330646A1 (enExample)
EP (1) EP3843846A4 (enExample)
JP (2) JP7583710B2 (enExample)
CN (1) CN112912141B (enExample)
AU (1) AU2019329835B2 (enExample)
CA (1) CA3110877A1 (enExample)
WO (1) WO2020046991A1 (enExample)

Families Citing this family (11)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CA3071525A1 (en) 2017-08-02 2019-02-07 Spinogenix, Inc. Benzothiazole and related compounds
ES3032326T3 (en) 2019-01-31 2025-07-17 Spinogenix Inc Solid forms of a promoter of spinogenesis
EP4178955A1 (en) 2020-07-11 2023-05-17 Pfizer Inc. Antiviral heteroaryl ketone derivatives
US11351149B2 (en) 2020-09-03 2022-06-07 Pfizer Inc. Nitrile-containing antiviral compounds
JP2024507224A (ja) * 2021-02-22 2024-02-16 スピノジェニックス， インコーポレイテッド 脊髄傷害または損傷を処置する方法
US20240180920A1 (en) * 2021-03-23 2024-06-06 Spinogenix, Inc. Certain fascin binding compounds for spinogenesis
AU2024244089A1 (en) * 2023-04-03 2025-10-30 Spinogenix, Inc. Methods of dosing spinogenic compounds
CN121773104A (zh) * 2023-06-30 2026-03-31 北京双鹤润创科技有限公司 肌成束蛋白抑制剂
WO2025184576A1 (en) * 2024-02-29 2025-09-04 Spinogenix, Inc. Methods for prevention and treatment of depression
WO2026050308A1 (en) * 2024-08-26 2026-03-05 Spinogenix, Inc. Benzothiazole compound for treating or preventing diabetes
WO2026050303A1 (en) * 2024-08-26 2026-03-05 Spinogenix, Inc. Methods of treating ophthalmic diseases

Citations (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP2015502913A (ja) 2011-09-14 2015-01-29 プロクシマゲン リミテッド 新規な酵素阻害剤化合物
JP2015526472A (ja) 2012-08-22 2015-09-10 コーネル ユニヴァーシティー ファスシンを阻害する方法

Family Cites Families (13)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US3845770A (en) 1972-06-05 1974-11-05 Alza Corp Osmatic dispensing device for releasing beneficial agent
US4326525A (en) 1980-10-14 1982-04-27 Alza Corporation Osmotic device that improves delivery properties of agent in situ
US5364620A (en) 1983-12-22 1994-11-15 Elan Corporation, Plc Controlled absorption diltiazem formulation for once daily administration
US5023252A (en) 1985-12-04 1991-06-11 Conrex Pharmaceutical Corporation Transdermal and trans-membrane delivery of drugs
US4992445A (en) 1987-06-12 1991-02-12 American Cyanamid Co. Transdermal delivery of pharmaceuticals
US5001139A (en) 1987-06-12 1991-03-19 American Cyanamid Company Enchancers for the transdermal flux of nivadipine
US4902514A (en) 1988-07-21 1990-02-20 Alza Corporation Dosage form for administering nilvadipine for treating cardiovascular symptoms
AU2012239977B9 (en) 2011-04-07 2016-11-17 Sloan-Kettering Institute For Cancer Research Migrastatins and uses thereof
WO2013013240A2 (en) * 2011-07-21 2013-01-24 Theracrine, Inc. Macrocyclic compounds and related compositons and methods of use
WO2015127125A1 (en) * 2014-02-20 2015-08-27 Cornell University Compounds and methods for inhibiting fascin
CA3010445A1 (en) * 2016-01-05 2017-07-13 The Regents Of The University Of California Benzothiazole amphiphiles
TWI586367B (zh) 2016-03-28 2017-06-11 蔡懷楨 磷酸甘油酯激酶增加神經突生長及／或治療神經性疾病的用途
CA3071525A1 (en) * 2017-08-02 2019-02-07 Spinogenix, Inc. Benzothiazole and related compounds

Patent Citations (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP2015502913A (ja) 2011-09-14 2015-01-29 プロクシマゲン リミテッド 新規な酵素阻害剤化合物
JP2015526472A (ja) 2012-08-22 2015-09-10 コーネル ユニヴァーシティー ファスシンを阻害する方法

Also Published As

Publication number Publication date
CN112912141B (zh) 2026-03-31
CA3110877A1 (en) 2020-03-05
EP3843846A4 (en) 2022-09-07
US20210330646A1 (en) 2021-10-28
WO2020046991A1 (en) 2020-03-05
US20240423962A1 (en) 2024-12-26
CN112912141A (zh) 2021-06-04
EP3843846A1 (en) 2021-07-07
JP2025016676A (ja) 2025-02-04
AU2019329835A1 (en) 2021-04-15
JP2021535159A (ja) 2021-12-16
AU2019329835B2 (en) 2025-05-29

Similar Documents

Publication Publication Date Title
JP2025016676A (ja) スパイン形成のためのファシン結合化合物
US10434109B2 (en) Compositions for treating neurological disorders
JP7212781B2 (ja) 神経保護剤と組み合わせたｓａｒｍ１の阻害剤
JP5933258B2 (ja) ゾニサミドおよびアカンプロセートを用いるアルツハイマー病および関連障害の処置のための併用組成物
TWI298255B (en) Use of optically pure (s.s)-reboxetine in the manufacture of a medicament for the treatment or prevention of fibromyalgia or another somatoform disorder
US20050159364A1 (en) Copper antagonist compounds
JP2014088421A (ja) 血管透過性およびアポトーシスの阻害方法
EA032881B1 (ru) Применение торасемида для лечения болезни альцгеймера или родственного болезни альцгеймера расстройства или травмы спинного мозга
US12486287B2 (en) Solid forms of a promoter of spinogenesis
JP2025165957A (ja) ブルトン型チロシンキナーゼ阻害剤を使用したシェーグレン症候群を処置する方法
CN112566641A (zh) 治疗和/或预防与年龄相关的神经变性的进展和/或发病的方法和组合物
US20160206603A1 (en) Composition comprising torasemide and baclofen for treating neurological disorders
CN101677972A (zh) 一种用于治疗神经变性疾病的奈拉美生的新组合物
CA3187086A1 (en) Methods for reducing glycosphingolipid concentration in brain tissue and methods of treatment of neurodegenerative diseases involving the same
WO2025184576A1 (en) Methods for prevention and treatment of depression
JP2026516175A (ja) 微小血管機能障害および関連疾患の診断および治療のための組成物および方法
AU2024244089A1 (en) Methods of dosing spinogenic compounds
JP2024510632A (ja) スパイン形成のためのある特定のファスシン結合化合物
JP2023505054A (ja) 処置方法
EA041892B1 (ru) Способы и композиции для лечения ассоциированных со старением нарушений с применением ccr3-ингибиторов

Legal Events

Date Code Title Description
A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20220817

A621 Written request for application examination

Free format text: JAPANESE INTERMEDIATE CODE: A621

Effective date: 20220817

A131 Notification of reasons for refusal

Free format text: JAPANESE INTERMEDIATE CODE: A131

Effective date: 20230719

A601 Written request for extension of time

Free format text: JAPANESE INTERMEDIATE CODE: A601

Effective date: 20231018

A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20231219

A131 Notification of reasons for refusal

Free format text: JAPANESE INTERMEDIATE CODE: A131

Effective date: 20240329

A601 Written request for extension of time

Free format text: JAPANESE INTERMEDIATE CODE: A601

Effective date: 20240628

A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20240828

TRDD Decision of grant or rejection written
A01 Written decision to grant a patent or to grant a registration (utility model)

Free format text: JAPANESE INTERMEDIATE CODE: A01

Effective date: 20241004

A61 First payment of annual fees (during grant procedure)

Free format text: JAPANESE INTERMEDIATE CODE: A61

Effective date: 20241101

R150 Certificate of patent or registration of utility model

Ref document number: 7583710

Country of ref document: JP

Free format text: JAPANESE INTERMEDIATE CODE: R150